Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026

Rhea-AI Summary

Skye Bioscience (Nasdaq: SKYE) will report 2025 fourth-quarter and full-year financial results and provide a business update on March 10, 2026. A press release will be issued after market close, followed by a conference call at 1:30 p.m. PT / 4:30 p.m. ET.

Investors can access a live webcast, financial tables, and an investor presentation on Skye's Investor Relations website; a replay and transcript will be posted after the call.

News Market Reaction – SKYE

-0.35%

3 alerts

-0.35% News Effect

-$87K Valuation Impact

$25M Market Cap

0.4x Rel. Volume

On the day this news was published, SKYE declined 0.35%, reflecting a mild negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $87K from the company's valuation, bringing the market cap to $25M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Earnings call date: March 10, 2026 Earnings call time PT: 1:30 p.m. PT Earnings call time ET: 4:30 p.m. ET +1 more

4 metrics

Earnings call date March 10, 2026 2025 Q4 and full-year results announcement

Earnings call time PT 1:30 p.m. PT Start time of conference call

Earnings call time ET 4:30 p.m. ET Start time of conference call

Call arrival window 5–10 minutes Recommended early join time before call

Market Reality Check

Price: $0.7414 Vol: Volume 125,497 is below t...

low vol

$0.7414 Last Close

Volume Volume 125,497 is below the 20-day average of 237,464 (relative volume 0.53). low

Technical Trading below 200-day MA of 2.23, with shares at 0.7406.

Peers on Argus

Peers show mixed moves: AVTX down 2.96%, while CRDF, FBRX, HURA, and ZURA are up...

1 Down

Peers show mixed moves: AVTX down 2.96%, while CRDF, FBRX, HURA, and ZURA are up between 4.21% and 6.88%. This suggests stock-specific factors around SKYE’s earnings date rather than a unified sector move.

Historical Context

5 past events · Latest: Feb 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 02	Phase 2a extension	Positive	-7.9%	Interim 52-week CBeyond extension data showing 22.3% mean weight loss combo.
Jan 29	Preclinical data	Positive	-5.0%	Preclinical nimacimab data at Keystone Obesity conference in DIO mouse models.
Jan 21	Conference poster	Positive	+0.8%	Announcement of upcoming poster on nimacimab in obesity models at Keystone.
Jan 12	Corporate outlook	Positive	-4.0%	2026 outlook detailing CBeyond extension updates and planned Phase 2b study.
Jan 05	Collaboration deal	Positive	-2.3%	Global collaboration with Halozyme to use ENHANZE for nimacimab delivery.

Pattern Detected

Recent fundamentally positive updates on nimacimab and corporate outlook often saw negative next-day price reactions, indicating a pattern of divergence between news tone and immediate market response.

Recent Company History

Over the past months, SKYE has focused on advancing nimacimab for obesity, with multiple updates on preclinical data, Phase 2a clinical extension results, and a 2026 corporate outlook. A collaboration with Halozyme supports higher-dose subcutaneous delivery and planned Phase 2b obesity testing in mid-2026. Despite positive scientific and strategic milestones and conference presentations, four of the last five news events saw negative 24-hour price reactions, highlighting a recurring divergence between news flow and short-term trading.

Market Pulse Summary

This announcement sets March 10, 2026 as the date for Skye’s 2025 fourth-quarter and full-year resul...

Analysis

This announcement sets March 10, 2026 as the date for Skye’s 2025 fourth-quarter and full-year results call, scheduled for 1:30 p.m. PT/4:30 p.m. ET. It follows a series of clinical, strategic, and collaboration updates around nimacimab and obesity programs. Investors may focus on detailed financials, cash usage, and how management frames upcoming Phase 2b plans and milestones compared with prior CBeyond and corporate outlook disclosures.

AI-generated analysis. Not financial advice.

SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Tuesday, March 10th at 1:30 p.m. PT/4:30 p.m. ET to discuss its 2025 fourth quarter and full-year financial results and business update. An earnings press release will be issued after the market closes on March 10th.

The live webcast of the call can be accessed at the Skye Investor Relations website, along with the company's earnings press release, financial tables, and investor presentation. Please join the call 5-10 minutes prior to the scheduled start time. Following the call, a replay and transcript will be available at the same website.

About Skye Bioscience

Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2a clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.

CONTACTS

Investor Relations

ir@skyebioscience.com
(858) 410-0266

LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306

Media Inquiries

LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(415) 269-7757

FAQ

When will Skye Bioscience (SKYE) announce its Q4 and full-year 2025 results?

Skye will release 2025 fourth-quarter and full-year results on March 10, 2026, after market close. According to the company, a conference call will follow on the same day at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and business update.

How can investors access the Skye Bioscience (SKYE) earnings call on March 10, 2026?

Investors can join the live webcast via Skye's Investor Relations website and call in for the conference. According to the company, the webcast will include the earnings press release, financial tables, and an investor presentation.

Will Skye Bioscience (SKYE) provide financial tables and investor presentation with the March 10, 2026 release?

Yes. The company will post financial tables and an investor presentation alongside the earnings press release. According to the company, these materials will be available on the Skye Investor Relations website at the time of the release.

What time should I join the Skye Bioscience (SKYE) March 10, 2026 conference call?

Join the call 5–10 minutes early; it starts at 1:30 p.m. PT / 4:30 p.m. ET. According to the company, arriving early ensures uninterrupted access to the live webcast and any dial-in procedures.

Will a replay or transcript be available after Skye Bioscience's (SKYE) March 10, 2026 call?

Yes. A replay and transcript will be posted after the conference call on the Skye Investor Relations website. According to the company, both the replay and transcript will remain accessible following the live event.

What topics will Skye Bioscience (SKYE) cover in the March 10, 2026 webcast?

The webcast will cover 2025 fourth-quarter and full-year financial results and a business update. According to the company, the call will discuss financial results and related investor materials including financial tables and an investor presentation.